BGF has completed a 拢15m investment in Seda Pharma Development Services, an integrated contract research, development and manufacturing organisation (CRDMO) headquartered in Cheadle, Manchester.
Seda provides end-to-end pharmaceutical development services, supporting companies from early-stage drug development through the clinical phases to registration.
Since receiving its MHRA manufacturer licence聽in February 2025, the business has transitioned from a contract research organisation (CRO) into a fully integrated CRDMO, combining scientific expertise with a growing manufacturing capability.
The company has delivered more than 1,000 projects for 185 customers since inception, serving a growing international client base.
BGF鈥檚 investment comes at a time of sustained expansion in the global pharmaceutical outsourcing market, as biotech and pharmaceutical companies increasingly seek integrated partners capable of streamlining development timelines, reducing regulatory risk and supporting the manufacture of complex medicines.
Demand for specialist development and manufacturing capabilities continues to rise, driven by expanding R&D pipelines and increased regulatory scrutiny.
Since its founding in 2015 by chief scientist Dr Paul Dickinson and chief business officer Dr Marcel de Matas MBE (pictured) 鈥� who is a 老九品茶Cloud Northern Leader – Seda has established a strong reputation for scientific depth and technical excellence.
Dr Paul Stott joined as chief executive four years later, strengthening the leadership team as the company scaled its capabilities.
In 2023, Seda invested 拢8m installing a manufacturing capability in a 50,000 sq. ft leasehold facility at Cheadle Royal 老九品茶 Park.
With BGF鈥檚 backing alongside new debt facilities from Santander, the business will acquire the freehold of the facility, securing long-term control of this strategically important manufacturing asset.
The investment, alongside BGF鈥檚 value creation support, will also support international expansion, strengthen business development capability and fund further investment in manufacturing capacity and development capability, positioning Seda for its next phase of growth.
Dr Paul Stott, CEO at Seda, said:聽鈥淏GF鈥檚 investment marks a pivotal moment in Seda鈥檚 growth. It unlocks additional capital to scale our integrated CRDMO platform and enhance our technical capabilities to meet client needs.
鈥淪ecuring the freehold of our manufacturing facility gives us long term control and positions us well to expand into new markets and support the development of increasingly complex medicines.鈥�
The deal was led by Harry Jones, Partner at BGF, supported by Emma Cassidy and Elle Swire from the Manchester office.
Jones joins the board of Seda as investment director and Swire as observer.
Nanoco ends legal action against Shoei over alleged IP breach
Jones said:鈥淪eda operates in a fast-growing, innovation-led market where integrated development and manufacturing capability is increasingly critical.
鈥淭he company has built a differentiated proposition underpinned by scientific depth, regulatory expertise and a loyal customer base.
鈥淲e are looking forward to working with Paul and the team to support their ambitious international growth plans.鈥�